Search Results
Dec 03, 2025, 08:00 ET STRM.BIO Awarded ARPA-H Contract to Advance Megakaryocyte-Derived Vesicle Platform for In Vivo Cell Engineering and Gene Therapy
develop in vivo CAR-T therapeutics. The partnership will leverage Ginkgo's expertise in RNA construct design and immune cell engineering, UBC's expertise in the design and biology of self-amplifying RNA (saRNA), and ABS's expertise in vesicle production and bioprocessing to advance the novel in
More news about: STRM.BIO
Dec 03, 2025, 08:00 ET Avance Biosciences Launches Potency & Cell-Based Assay Center in Houston
functional cell-based assays under GMP compliance. Located in Houston, the Center supports clients across the development and manufacturing of biologics, RNA therapeutics, vaccines, and cell and gene therapies.
More news about: Avance Biosciences, Inc.
Dec 02, 2025, 10:07 ET Katalyze AI Appoints Chief AI Officer to Advance Agentic AI Capabilities in Pharmaceutical Manufacturing
Hannes brings more than a decade of experience in machine learning, genomics, and at-scale computational systems. His background in RNA biology, alternative splicing, microexon detection, and protein interactions directly supports Katalyze AI's strategy to build agents that can analyze
More news about: Katalyze AI
Dec 02, 2025, 09:00 ET Melanoma Research Alliance Launches Melanoma Biorepository to Accelerate Research and Improve Patient Outcomes
regardless of where they receive care. These specimens may be used for immediate research, stored for future studies or further processed into DNA, RNA or protein for advanced analysis. They may also support the creation of vital scientific resources such as cell lines, tissue microarrays, and patient-derived
More news about: Melanoma Research Alliance
Dec 01, 2025, 18:59 ET Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their Rights
multimedia:https://www.prnewswire.com/news-releases/halper-sadeh-llc-encourages-rna-tcbx-atxs-fsun-shareholders-to-contact-the-firm-to-discuss-their-rights-302629610.htmlSOURCE
More news about: Halper Sadeh LLP
Dec 01, 2025, 15:20 ET $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--TCBX, RNA, ATXS, and FSUN
RNA) related to its sale to Novartis AG. Under the terms of the proposed transaction, Avidity shareholders will receive $72.00 per share in cash.Click
More news about: Monteverde & Associates PC
Dec 01, 2025, 11:19 ET Cystic Fibrosis Therapeutics Market Set to Reach USD 35.09 Billion by 2033 as Precision CFTR Modulator Therapies Transform Patient Outcomes
fastest evolution in its history, driven by:Next-gen CFTR modulators targeting rare mutationsCombination RNA therapies for non-respondersGene-editing and gene-replacement programs, particularly using CRISPRInhaled biologics addressing
More news about: DataM Intelligence 4 Market Research LLP
Dec 01, 2025, 09:00 ET Circular Genomics Announces Closure of $15 Million Series A Financing to Advance First-in-Class Circular RNA Platform for Early Detection of Alzheimer's Disease
GenomicsCircular Genomics is the world-leading developer of circular RNA-based precision medicine tools, data and diagnostics for precision neurology and psychiatry. Leveraging exclusive licenses and pioneering technologies in circular RNA, Circular Genomics is aiming to reshape the standard of care for the
More news about: Circular Genomics
Nov 28, 2025, 05:46 ET CRO Industry to Hit USD 127.77 Billion by 2030 Driven by Advanced Clinical Trial Models and Led by North America, Says Mordor Intelligence
Contract Manufacturing Market: The vaccine contract manufacturing market is segmented by vaccine type (inactivated, live-attenuated, rna), process (downstream {analytical & qc} and upstream {bacterial, mammalian}), scale of operations (preclinical, clinical, and more), end user (human
More news about: Mordor Intelligence Private Limited
Nov 27, 2025, 10:01 ET Orphan Drugs Market to Surge to USD 486.51 Billion by 2032 as Rare Disease Innovation, Gene Therapies & Precision Medicine Reshape Global Healthcare
people worldwide live with rare diseases, and over 95% of these conditions still have no approved treatment. Breakthroughs in gene therapy, RNA-based drugs, monoclonal antibodies, small-molecule precision therapies, and targeted biologics are now transforming outcomes for patients with neurological,
More news about: DataM Intelligence 4 Market Research LLP
Nov 27, 2025, 06:45 ET In-Silico Clinical Trials Market Set to Reach USD 6.39 Billion by 2033 as Pharma and MedTech Accelerate Digital-First Validation, AI Modeling & Virtual Patient Simulations
billion). The need to reduce R&D risk, optimize protocols, and predict patient responses drove rapid IST integration across small-molecule, biologics, RNA therapies, and cell & gene therapy pipelines.Medical Device ManufacturersMedical device companies accounted for 29% (USD
More news about: DataM Intelligence 4 Market Research LLP
Nov 26, 2025, 09:35 ET Exposing the Deadly Guesswork in Cancer Care: JOTO PR Signs First Ascent Biomedical
First Ascent Biomedical is revolutionizing cancer treatment with its AI-driven drug prediction platform. By integrating functional drug validation, DNA/RNA sequencing, and AI, the company identifies personalized therapies for all solid and liquid tumors, delivering actionable treatment plans to physicians
More news about: JOTO PR
Nov 25, 2025, 09:00 ET Lexogen Successfully Completes Large-Scale Human Primary Cell Next Gen Sequencing Project with Ochre Bio
company developing RNA medicines for under-treated chronic liver diseases. Ochre builds and integrates extensive human liver data, including proprietary gene perturbation and disease atlases, to make causal pathway predictions for target discovery and facilitate the development of RNA therapies. Ochre's
More news about: LEXOGEN
Nov 25, 2025, 09:00 ET Lexogen Successfully Completes Large-Scale Human Primary Cell Next Gen Sequencing Project with Ochre Bio
company developing RNA medicines for under-treated chronic liver diseases. Ochre builds and integrates extensive human liver data, including proprietary gene perturbation and disease atlases, to make causal pathway predictions for target discovery and facilitate the development of RNA therapies. Ochre's
More news about: LEXOGEN
Nov 25, 2025, 09:00 ET Lexogen schließt erfolgreich ein groß angelegtes Next-Gen-Sequenzierungsprojekt für menschliche Primärzellen mit Ochre Bio ab
die Entwicklung von RNA-Therapien zu unterstützen. Die firmeneigene Software OBELiX von Ochre ermöglicht die Analyse der Genbiologie in menschlichen Zellen, Gewebe und ganzen Lebern und bietet eine KI-basierte Discovery-Engine zur Priorisierung von Zielmolekülen. RNA-Seq-Daten mit hoher
More news about: LEXOGEN
Nov 25, 2025, 09:00 ET Lexogen achève avec succès un projet de séquençage nouvelle génération à grande échelle sur des cellules primaires humaines avec Ochre Bio
d'apprentissage automatique de séparer le véritable signal biologique du bruit technique. La technologie propriétaire THOR de Lexogen et le service expert RNA-Seq ont fourni des données exceptionnelles à grande échelle permettant de meilleures prédictions de cibles à l'avenir » déclare Quin Wills, fondateur
More news about: LEXOGEN
Nov 24, 2025, 09:56 ET NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS
mechanisms of ALS and Alzheimer's Disease (AD) that contribute to motor neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD.About NeuroSenseNeuroSense Therapeutics, Ltd. is a clinical-stage
More news about: NeuroSense
Nov 24, 2025, 09:00 ET Circular Genomics to Unveil New Data Highlighting Circular RNAs as a Transformative New Class of Blood-Based Biomarkers for Alzheimer's Disease at CTAD 2025
using circular RNA biomarkers in bloodDate/Time:Wednesday, December 3, 11:50 amAbout the circRNA PlatformCircular RNAs (circRNAs) are non-coding RNAs that are enriched in the brain and dysregulated in neurodegenerative diseases. Unlike linear RNA or protein biomarkers,
More news about: Circular Genomics
Nov 22, 2025, 07:50 ET 2025倫敦•金斯瑞生物科技全球產業論壇圓滿落幕：共話CGT新時代，創寫無限可能
Mello、賓夕法尼亞大學細胞免疫治療中心主任Carl June以及國際細胞與基因治療學會（ISCT）主席及董事會主席Miguel Forte發表了主旨演講。他們從科學、產業、臨床等視角出發，分享CGT最新技術突破與實踐經驗，為行業發展出謀劃策。2006年，Craig Mello博士因發現「RNA干擾（RNAi, RNA interference）機制」而榮獲諾貝爾生理學或醫學獎，他的研究奠定了現代核酸藥物與基因調控技術的基石。本次論壇，Craig Mello博士帶來了一場以「RNA干擾：信息烈焰中的分子火花」為主題的主旨演講。他指出，RNAi療法高度可編程，僅需重新設定序列即可生成新的寡核甘酸，生
More news about: 金斯瑞生物科技股份有限公司
Nov 21, 2025, 17:32 ET Exploring the Next Era of CGT and Unlocking Limitless Possibilities: The GenScript Biotech Global Forum London 2025 Wraps Up
intervene at the RNA level to control diseases at their source.Moderated by Dr. Julen Oyarzabal, CSO of Syngoi Technologies SL, the session "Gene Therapy and mRNA Therapeutics" brought together experts from both academia and industry: Dr. Sergio Linares Fernández, Unit Head of RNA Science Automation
More news about: GenScript Biotech Corporation
Nov 21, 2025, 17:30 ET $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-WTRG, RNA, FIZN, and TCBX
RNA) related to its sale to Novartis AG. Under the terms of the proposed transaction, Avidity shareholders will receive $72.00 per share in cash. Click
More news about: Monteverde & Associates PC
Nov 21, 2025, 16:39 ET Zymo Research Advances Wastewater Surveillance as Sponsor of the Microbes in Wastewater Symposium 2026
Quick-DNA/RNA™ Water Kit: Extracts and purifies total DNA/RNA from large volume water samples, concentrating viruses and low-abundance targets while removing inhibitors, including from raw influent wastewater.
More news about: Zymo Research Corp.
Nov 21, 2025, 12:39 ET Hackensack Meridian John Theurer Cancer Center Unveils Research at the 67th American Society of Hematology Annual Meeting
approval, 1999-2023 (ABSTRACT 25-9103)TechnologyB- and T-cell clonality using peripheral blood cell-free RNA (cfRNA) in liquid biopsy (ABSTRACT 25-7865) Not so exclusive: Co-mutations in JAK2, MPL and CALR define distinct hematologic and clonal
More news about: Hackensack Meridian John Theurer Cancer Center
Nov 21, 2025, 09:47 ET Cuidados combinados: como o skincare diário e os procedimentos estéticos se complementam para melhorar a qualidade da pele
https://doi.org/10.1016/j.jdermsci.2016.09.0153. Waibel J, Ziegler M, Nguyen TQ, Le JHTD, Qureshi A, Widgerow A, Meckfessel M. Comparative Bulk RNA-Seq Analysis of Poly-l-Lactic Acid Versus Calcium Hydroxylapatite Reveals a Novel, Adipocyte-Mediated Regenerative Mechanism of Action Unique to PLLA.
More news about: Galderma
Nov 20, 2025, 14:55 ET How Evf2 lncRNA Advances Research in Brain and Neurodevelopmental Disorders, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn how long non-coding RNA (lncRNA) mechanisms are reshaping neuroscience research and revealing new opportunities in functional genomics. Attendees will gain insight into how Evf2 lncRNA guides enhancer-gene regulation and organizes
More news about: Xtalks